David Fermin, MD
Advanced Heart Failure and Transplant Cardiology · Grand Rapids, MINPI 1447442215
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,651 of the $105,434 with a category attached, or 68.0%. E.r. Squibb & Sons, L.L.C. accounts for 85.6% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $38,974, more than ten times the $242 reported in 2019. Among advanced heart failure and transplant cardiology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 155 payments — averaging $680.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$90K
- Pfizer$8K
- Alnylam Pharmaceuticals Inc.$6K
- Abbott$689
- Boehringer Ingelheim$160
- Novo Nordisk$78
- plus $352 from 9 others
Across 41 payments — averaging $29,870 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1.1M
- Lexicon Pharmaceuticals, Inc.$73K
- Pfizer$16K
What the payments were for
- Consulting fees$26,23525%
- Speaking & faculty fees$71,65168%
- Travel & lodging$3,9664%
- Food & beverage$3,5093%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 87 | $90,250 |
| Pfizer | 30 | $8,000 |
| Alnylam Pharmaceuticals Inc. | 6 | $5,905 |
| Abbott | 8 | $689 |
| Boehringer Ingelheim | 3 | $160 |
| Novo Nordisk | 1 | $78 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $71 |
| Johnson & Johnson | 4 | $62 |
| Merck | 2 | $51 |
| Medtronic | 2 | $46 |
| AstraZeneca | 2 | $33 |
| Novartis | 2 | $30 |
| Akcea Therapeutics, Inc. | 1 | $21 |
| Amgen | 1 | $19 |
| Insmed, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$15,291
- VYNDAMAX$6,011
- ONPATTRO$3,690
- VYNDAQEL$1,575
- CardioMEMS HF System$283
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$191
- HeartMate 3 Left Ventricular Assist Device$153
- JARDIANCE$120
How this compares
$105,434 in reported general payments places this provider in the 95th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
See all advanced heart failure and transplant cardiology providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 256 | $6,421,107 |
| EntrestoSacubitril/Valsartan | 179 | $210,051 |
| EliquisApixaban | 184 | $203,447 |
| CamzyosMavacamten | 25 | $201,211 |
| FarxigaDapagliflozin Propanediol | 185 | $158,647 |
| JardianceEmpagliflozin | 103 | $99,139 |
| XareltoRivaroxaban | 35 | $37,591 |
| Metoprolol Succinate | 244 | $6,328 |
| Spironolactone | 385 | $5,335 |
| Eplerenone | 49 | $4,182 |
| Torsemide | 113 | $3,564 |
| Potassium Chloride | 54 | $1,895 |
| Atorvastatin Calcium | 101 | $1,832 |
| Carvedilol | 105 | $1,538 |
| Bumetanide | 15 | $1,376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $8,000 | $6,624,554440 claims |
| NovartisEntresto | $30 | $210,051179 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $90,250 | $201,21125 claims |
| AstraZenecaFarxiga | $33 | $158,647185 claims |
| Boehringer IngelheimJardiance | $160 | $99,139103 claims |
| Johnson & JohnsonXarelto | $62 | $37,59135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
Other advanced heart failure and transplant cardiology in Grand Rapids
- Michael DickinsonGrand Rapids$80K
- Sangjin LeeGrand Rapids$25K
- Matthew GonzalezGrand Rapids$22K
- Renzo Loyaga-RendonGrand Rapids$5K
- Ryan GrayburnGrand Rapids$4K
- Milena JaniGrand Rapids$3K
- Jennifer CowgerDetroit$165K
- Thomas CascinoAnn Arbor$39K
- Keith AaronsonAnn Arbor$22K
- Waleed Al-DarziDetroit$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.